Themis Medicare Ltd
Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]
- Market Cap ₹ 1,249 Cr.
- Current Price ₹ 136
- High / Low ₹ 317 / 115
- Stock P/E 52.2
- Book Value ₹ 34.8
- Dividend Yield 0.37 %
- ROCE 11.0 %
- ROE 7.70 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.90 times its book value
- Company has a low return on equity of 10.6% over last 3 years.
- Dividend payout has been low at 9.74% of profits over last 3 years
- Company has high debtors of 160 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
172 | 167 | 203 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 406 | |
153 | 156 | 171 | 184 | 184 | 182 | 166 | 181 | 299 | 287 | 330 | 356 | |
Operating Profit | 19 | 11 | 31 | 33 | 26 | 3 | 36 | 50 | 96 | 67 | 52 | 49 |
OPM % | 11% | 7% | 15% | 15% | 12% | 1% | 18% | 22% | 24% | 19% | 14% | 12% |
4 | 12 | 3 | 3 | 3 | 3 | 3 | 4 | 7 | 12 | 5 | 5 | |
Interest | 16 | 14 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 |
Depreciation | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 10 |
Profit before tax | 1 | 2 | 15 | 16 | 9 | -15 | 18 | 32 | 84 | 59 | 35 | 34 |
Tax % | -34% | -30% | -4% | 10% | 1% | -13% | 12% | 17% | 27% | 26% | 29% | 29% |
2 | 2 | 15 | 15 | 9 | -13 | 16 | 27 | 62 | 43 | 25 | 24 | |
EPS in Rs | 0.18 | 0.24 | 1.77 | 1.64 | 1.01 | -1.38 | 1.73 | 2.90 | 6.69 | 4.71 | 2.69 | 2.60 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 15% | 7% | 11% | 19% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 15% |
3 Years: | 1% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | 28% |
5 Years: | 9% |
3 Years: | -27% |
TTM: | -3% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 34% |
3 Years: | 18% |
1 Year: | -33% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 11% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 40 | 40 | 56 | 133 | 147 | 134 | 150 | 177 | 234 | 273 | 292 | 311 |
115 | 109 | 95 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 83 | |
67 | 67 | 61 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 102 | |
Total Liabilities | 231 | 225 | 220 | 278 | 292 | 299 | 326 | 338 | 384 | 456 | 490 | 506 |
91 | 92 | 89 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 | |
CWIP | 11 | 3 | 5 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 |
Investments | 10 | 11 | 11 | 12 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
119 | 119 | 115 | 133 | 153 | 162 | 191 | 192 | 226 | 280 | 308 | 320 | |
Total Assets | 231 | 225 | 220 | 278 | 292 | 299 | 326 | 338 | 384 | 456 | 490 | 506 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 11 | 19 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | 22 | 35 | |
-3 | -2 | -4 | -4 | -0 | -4 | -5 | -16 | -16 | -24 | -16 | -12 | |
2 | -15 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | -9 | -26 | |
Net Cash Flow | 8 | -6 | 2 | -0 | -1 | -3 | 2 | 16 | 1 | -8 | -3 | -3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 71 | 88 | 73 | 81 | 120 | 145 | 186 | 123 | 93 | 150 | 170 | 160 |
Inventory Days | 231 | 223 | 210 | 250 | 253 | 284 | 313 | 273 | 150 | 213 | 188 | 233 |
Days Payable | 250 | 272 | 152 | 163 | 156 | 186 | 171 | 144 | 79 | 123 | 126 | 142 |
Cash Conversion Cycle | 52 | 38 | 131 | 168 | 217 | 243 | 328 | 253 | 165 | 239 | 233 | 251 |
Working Capital Days | 63 | 68 | 53 | 74 | 132 | 134 | 178 | 154 | 125 | 177 | 181 | 181 |
ROCE % | 10% | 10% | 17% | 15% | 9% | -1% | 13% | 17% | 31% | 20% | 11% | 11% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report confirms full regulatory compliance for FY 2024-25.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 21 May
- Announcement under Regulation 30 (LODR)-Investor Presentation 20 May
- Corporate Action-Board approves Dividend 20 May
-
Announcement under Regulation 30 (LODR)-Change in Management
20 May - Approved FY25 results; recommended Rs.4.6Cr dividend; appointed auditors; approved $440K JV management fee MoU.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Oct 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPTREC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
Business Segments[1]
A) Hospital Business - Critical Care Division, Intensive Care Division, Institution Business, Exports. Hospital Business is a major growth driver. Critical Care and Intensive Care teams contribute to building Hospital Business with new launches and increased hospital/doctor’s coverage.